CAR T Cell Therapy Involves Genetically Modifying The Patient’s T Cells To Recognize And Attack Cancer Cells

CAR T Cell Therapy

CAR T Cell Therapy is a new type of immunotherapy that targets the immune system to kill cancer cells. It is used to treat certain blood cancers, like leukemia and lymphoma. It is also being studied in solid tumors.

The applications of CAR T Cell Therapy are vast and include hematologic malignancies and solid tumors such as glioblastoma, advanced sarcoma, multiple myeloma, and pancreatic cancer. CAR T cells can be used alone or in combination with other cancer therapies to treat the disease and improve outcomes.

T cells are natural killer cells that recognize and attack cancer cells based on their molecular surface structures. They are also able to destroy healthy tissues that are damaged by cancerous cells. T cells release cytokines, which are chemical messengers that stimulate and direct other immune system components to respond to the presence of cancerous cells.

Global CAR T Cell Therapy Market Is Estimated To Be Valued At US$ 2.26 Billion In 2022 And Is Expected To Exhibit A CAGR Of 20.9 % During The Forecast Period (2022-2030).

Researchers make T cells with a genetically engineered receptor to target a particular tumor antigen. Then they add these modified T cells back into the patient’s bloodstream.

Many studies are investigating combining CAR T Cell Therapy with other therapies that can improve outcomes. These combinatorial treatments may include chemotherapy, radiation therapy, cytokine therapies and checkpoint blockades. Some scientists are also developing oncolytic viruses to help deliver the CAR T cells to the tumor.

Currently, CAR T cell therapy is only available in a clinical trial. Most people who receive it stay in the hospital so their healthcare providers can monitor them for signs of side effects. Whereas some clinics have begun to offer CAR T cell therapy in an outpatient setting.

There are many different types of cancer that can be treated with CAR T Cell Therapy. Several have been approved by the FDA, including leukemias and lymphomas. Other cancers such as breast cancer, non-small cell lung cancer, and solid tumors are being studied with CAR T therapy.

Seattle Genetics, Inc., and Merck declared their collaboration in September 2020, for new strategic oncology studies. Under the partnership they will be conducting various development program in several cancers.